S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

Xenon Pharmaceuticals (XENE) Stock Forecast, Price & News

+0.95 (+3.18%)
(As of 05/17/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
304,846 shs
Average Volume
458,024 shs
Market Capitalization
$1.64 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive XENE News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Xenon Pharmaceuticals logo

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.


Xenon Pharmaceuticals Tops Q1 EPS by 6c
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$18.44 million
Book Value
$10.51 per share


Net Income
$-78.88 million
Net Margins
Pretax Margin




Free Float
Market Cap
$1.64 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.80 out of 5 stars

Medical Sector

800th out of 1,426 stocks

Pharmaceutical Preparations Industry

389th out of 680 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

Is Xenon Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Xenon Pharmaceuticals stock.
View analyst ratings for Xenon Pharmaceuticals
or view top-rated stocks.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Xenon Pharmaceuticals

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) announced its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.03. Xenon Pharmaceuticals had a negative trailing twelve-month return on equity of 20.94% and a negative net margin of 360.80%. During the same quarter in the prior year, the business earned ($0.42) earnings per share.
View Xenon Pharmaceuticals' earnings history

What price target have analysts set for XENE?

6 brokers have issued 1-year target prices for Xenon Pharmaceuticals' shares. Their forecasts range from $40.00 to $48.00. On average, they anticipate Xenon Pharmaceuticals' stock price to reach $44.00 in the next twelve months. This suggests a possible upside of 42.5% from the stock's current price.
View analysts' price targets for Xenon Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Xenon Pharmaceuticals' key executives?
Xenon Pharmaceuticals' management team includes the following people:
  • Dr. Simon N. Pimstone FRCPC, M.B. ChB., M.D., Ph.D., Exec. Chairman (Age 54, Pay $787.78k)
  • Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA, Pres, CEO & Director (Age 46, Pay $667.55k)
  • Ms. Sherry Aulin, Chief Financial Officer (Age 38)
  • Ms. Jodi Regts M.B.A., B.A., MBA, VP of Corp. Affairs & Investor Relations
  • Ms. Shelley McCloskey B.A., Sr. VP of HR (Age 62)
  • Dr. Robin P. Sherrington, Exec. VP of Strategy & Innovation (Age 61)
  • Dr. James R. Empfield Ph.D., Exec. VP of Drug Discovery (Age 61)
  • Ms. Sheila M. Grant M.B.A., M.Sc., MBA, Sr. VP of R&D Operations
  • Dr. Christopher E. Von Seggern M.B.A., M.P.H., Ph.D., M.P.H. M.B.A, Chief Commercial Officer (Age 43)
  • Dr. Kenneth Sommerville, Interim Chief Medical Officer
What other stocks do shareholders of Xenon Pharmaceuticals own?
What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Polar Capital Holdings Plc (4.12%), Lord Abbett & CO. LLC (3.37%), Great Point Partners LLC (1.73%), Rock Springs Capital Management LP (1.59%), Goldman Sachs Group Inc. (1.36%) and BlackRock Inc. (1.16%). Company insiders that own Xenon Pharmaceuticals stock include Christopher John Kenney, Frank A Holler, James R Empfield, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends for Xenon Pharmaceuticals

Which major investors are selling Xenon Pharmaceuticals stock?

XENE stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bank of New York Mellon Corp, Kynam Capital Management LP, Invesco Ltd., Affinity Asset Advisors LLC, Parkman Healthcare Partners LLC, Great Point Partners LLC, and Ensign Peak Advisors Inc. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, James R Empfield, Sherrington Robin, and Simon N Pimstone.
View insider buying and selling activity for Xenon Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Xenon Pharmaceuticals stock?

XENE stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Polar Capital Holdings Plc, Eversept Partners LP, CI Investments Inc., Citigroup Inc., Walleye Capital LLC, Candriam Luxembourg S.C.A., and Rock Springs Capital Management LP. Company insiders that have bought Xenon Pharmaceuticals stock in the last two years include Christopher John Kenney, and Seggern Christopher Von.
View insider buying and selling activity for Xenon Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $30.87.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals has a market capitalization of $1.64 billion and generates $18.44 million in revenue each year. The biopharmaceutical company earns $-78.88 million in net income (profit) each year or ($1.79) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

Xenon Pharmaceuticals employs 149 workers across the globe.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is www.xenon-pharma.com.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at [email protected], or via fax at 604-484-3450.

This page was last updated on 5/18/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.